RecruitingRecruiting
Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics
NCT05270733 · University Hospitals Cleveland Medical Center
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics in Ustekinumab Responders Versus Non-responders
About this study
Psoriasis is a chronic systemic skin disease in which pro-inflammatory molecules contribute to the development of scaled inflamed skin and other disease-associated comorbidities such as increased risk of depression, heart attack, stroke, and metabolic syndrome. Some lesion-derived cytokines/chemokines are released into systemic circulation and increase lesional severity. Given their importance in the pathogenesis of psoriasis, the interleukins 12 (IL-12) and 23 (IL-23) are significant targets of biologic therapies.
Importantly, psoriasis patients exhibit variable responses to treatments targeting interleukins; one size does not fit all for these therapeutics. Our preliminary data demonstrates individual skin improvement (Responders) as well as lack of skin improvement (Non-Responders) in patients treated with monoclonal antibody therapy specifically targeting the shared (p40) subunit common to IL-12 and IL-23 (ustekinumab/Stelara). Interestingly, some Non-Responders to ustekinumab respond well to inhibition of the IL-23 pathway via the unique p19 subunit. We hypothesize that the pattern of differentially expressed genes (DEGs) among Responders and Non-Responders following anti-IL-12 and anti-IL-23 therapy may enable us to predict the likelihood of patient response to p40 antagonism as well as antagonism of the p19 subunit of IL-23. Single cell transcriptome analysis will be used to generate gene expression patterns that identify variable patient response patterns (endotypes).
Eligibility criteria
Inclusion Criteria:
* Diagnosed with plaque-type psoriasis defined by either:
* A board-certified dermatologist, OR
* Dermatology Nurse Practitioner, OR
* Skin punch biopsy
* Insurance that includes an anti-p40 biologic (ustekinumab/.Stelara) and at least one anti-p19 biologic (guselkumab/Tremfya or risankizumab/Skyrizi)
* Must be naive to ustekinumab, guselkumab, and risankizumab.
* Involvement of body surface area (BSA) of at least 10% at screening and baseline visit.
* Able to give informed consent under IRB approval procedures
Exclusion Criteria:
* Pregnant, breastfeeding, or planning to get pregnant 8 weeks before, during, and 8 weeks after the study.
* Inability to provide informed consent
* Inability to secure ustekinumab and either gusekumab or risankizumab for use while on trial
* Use of tanning booths for at least 4 weeks prior to baseline visit
* Current or recent use of topical steroid, tar, phototherapy, Vitamin D, or retinoid therapy to target lesions for at least 2 weeks prior to baseline visit and for duration of trial
* Current or recent use of systemic or biologic therapy for at least 8 weeks prior to baseline visit
* Patients with psoriatic arthritis or other rheumatologic diseases (e.g., Crohn's disease).
Study design
Enrollment target: 56 participants
Allocation: na
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2022-11-10
Estimated completion: 2026-12-31
Last updated: 2026-04-02
Interventions
Drug: Ustekinumab
Primary outcomes
- • Identification of a unique differentially expressed gene set in patients with psoriasis that may predict disease response following antagonism to IL-12 and/or IL-23. (24 weeks)
Sponsor
University Hospitals Cleveland Medical Center · other
With: LEO Foundation, Case Western Reserve University
Contacts & investigators
ContactAmy Johnson, MD · contact · Amy.Johnson@UHhospitals.org · 216-286-7369
ContactAmanda Davies, MBA · contact · Amanda.Davies@UHhospitals.org · 216-844-7834
InvestigatorKevin Cooper, MD · principal_investigator, University Hospitals Cleveland Medical Center
All locations (1)
University Hospitals Cleveland Medical CenterRecruiting
Cleveland, Ohio, United States